Brind.

Amylyx Pharmaceuticals received a Buy rating on its stock, noting that the company benefits from Trump-era tariffs and onshoring trends.

2 reports, 1 independent Updated Jun 30

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Amylyx Pharmaceuticals received a Buy rating on its stock, noting that the company benefits from Trump-era tariffs and onshoring trends.

Who's involved

What this event is mainly about

Amylyx Pharmaceuticals Donald Trump Leerink partners

Keep exploring

The entities involved

Amylyx Pharmaceuticals
American biopharmaceutical company
- Mizuho analysts increased their price target on Amylyx Pharmaceuticals, with the news being reported by Benzinga on July 20, 2026.Sun 06:52
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
- Netanyahu and Katz warned Iran of consequences while US strikes targeted the Iranian regime.16:58
- U.S. trade policy is hindering Canadian market access.16:57
Leerink partners
U.S. investment bank
- Leerink Partners and Barclays raised price targets on Elevance Health, while MarketBeat reported consensus ratings.15:16
- Leerink Partners began coverage on Novogen Limited shares on October 20, 2026.Tue 14:18

Coverage

Newest first; wire copies grouped

Aug 19Insider MonkeyH.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm ‘Buy’ Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is included in our list of the 11 Best Single

1 more outlet ran the same wire story

Jun 30yahoo.com